Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
INJ price prediction – Can Injective’s SEC filing trigger a breakout above $5.20?

INJ price prediction – Can Injective’s SEC filing trigger a breakout above $5.20?

AMBCryptoAMBCrypto2026/07/17 18:09
By:AMBCrypto

Injective [INJ] traded back above

$5
as the token attempted to extend its recovery from June lows, with buyers now facing resistance around the
$5.20
region.

The latest price move comes as Injective filed its transfer agent registration with the U.S. Securities and Exchange Commission [SEC]. This is part of the blockchain network’s push to bring on-chain regulated real-world assets [RWAs] and securities infrastructure.

Injective files for SEC transfer-agent registration

Injective announced on

July 1
6 that it had officially filed its transfer agent registration with the SEC.

@media only screen and (min-width: 0px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 50px; transition: min-height 0.3s ease; } } @media only screen and (min-width: 640px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 90px; } }
AD

Transfer agents maintain official ownership records for securities and process changes when those assets change hands. Injective wants to bring this function on-chain, allowing the ownership record to exist on the same blockchain as the tokenized security rather than relying on a separate off-chain database.

According to Injective, moving the transfer-agent function on-chain could allow market participants to record and transfer ownership of tokenized securities within seconds while reducing the need for multiple intermediaries to reconcile transactions.

The filing begins the registration process and should not be interpreted as SEC approval or confirmation that Injective is already operating as a registered transfer agent.

Regulatory push extends beyond the U.S.

The SEC filing forms part of Injective’s broader push to expand its regulated financial infrastructure.

Injective said the announcement came hours after it published its MiCAR whitepaper, which the project says will support its expansion across European Union member states within the region’s regulatory framework.

Together, the developments highlight Injective’s efforts to position its blockchain infrastructure for institutional and regulated markets across the U.S. and Europe.

However, the developments have yet to trigger a decisive breakout for INJ.

Can INJ break above $5.20?

At press time, INJ was trading at approximately

$5.05
, with the latest
12-hour
candle gaining around
2.5%
.

The token has recovered considerably since falling towards

$4.10
in late June. However, its price action throughout July has largely remained within a consolidation range between approximately
$4.50 and $5.20
.

INJ price prediction – Can Injective’s SEC filing trigger a breakout above $5.20? image 0 Source: TradingView

The Relative Strength Index [RSI] stood at

56.20
, above the neutral
50
level, suggesting that buying momentum had strengthened. However, the indicator remained well below overbought territory, leaving room for further upside if demand increases.

The immediate challenge is the

$5.20
region, which has repeatedly limited INJ’s recovery attempts during July. A decisive move above this area could signal a breakout from the recent consolidation range and strengthen the case for an extended recovery.

Failure to overcome the resistance, however, could leave INJ range-bound and expose the token to another test of support around the lower end of its recent trading range.

Final Summary

  • Injective has filed for SEC transfer-agent registration to bring official ownership records for tokenized securities on-chain.
  • INJ has recovered above $5 with its RSI rising to 56.20. Still, the token must overcome resistance around $5.20 to confirm a breakout from its July consolidation range.

 

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales